Impact of ferumoxytol vs gadolinium on 4D flow cardiovascular magnetic resonance measurements in small children with congenital heart disease

Sarah E. Kollar1*, Michelle L. Udine1, Jason G. Mandell2, Russell R. Cross1, Yue-Hin Loke1 and Laura J. Olivieri1

Abstract

Background: Cardiovascular magnetic resonance (CMR) allows for time-resolved three-dimensional phase-contrast (4D Flow) analysis of congenital heart disease (CHD). Higher spatial resolution in small infants requires thinner slices, which can degrade the signal. Particularly in infants, the choice of contrast agent (ferumoxytol vs. gadolinium) may influence 4D Flow CMR accuracy. Thus, we investigated the accuracy of 4D Flow CMR measurements compared to gold standard 2D flow phase contrast (PC) measurements in ferumoxytol vs. gadolinium-enhanced CMR of small CHD patients with shunt lesions.

Methods: This was a retrospective study consisting of CMR studies from complex CHD patients less than 20 kg who had ferumoxytol or gadolinium-enhanced 4D Flow and standard two-dimensional phase contrast (2D-PC) flow collected. 4D Flow clinical software (Arterys) was used to measure flow in great vessels, systemic veins, and pulmonary veins. 4D Flow accuracy was defined as percent difference or correlation against conventional measurements (2D-PC) from the same vessels. Subgroup analysis was performed on two-ventricular vs single-ventricular CHD, arterial vs venous flow, as well as low flows (defined as < 1.5 L/min) in 1V CHD.

Results: Twenty-one ferumoxytol-enhanced and 23 gadolinium-enhanced CMR studies were included, with no difference in age (2.1 ± 1.6 vs. 2.3 ± 1.9 years, p = 0.70), patient body surface area (0.50 ± 0.2 vs. 0.52 ± 0.2 m², p = 0.67), or vessel diameter (11.4 ± 5.2 vs. 12.4 ± 5.6 mm, p = 0.22). Ten CMR studies with single ventricular CHD were included. Overall, ferumoxytol-enhanced 4D flow CMR measurements demonstrated less percent difference to 2D-PC when compared to gadolinium-enhanced 4D Flow CMR studies. In subgroup analyses of arterial vs. venous flows (high velocity vs. low velocity) and low flow in single ventricle CHD, ferumoxytol-enhanced 4D Flow CMR measurements had stronger correlation to 2D-PC CMR. The contrast-to-noise ratio (CNR) in ferumoxytol-enhanced studies was higher than the CNR in gadolinium-enhanced studies.

Conclusions: Ferumoxytol-enhanced 4D Flow CMR has improved accuracy when compared to gadolinium 4D Flow CMR, particularly for infants with small vessels in CHD.

Keywords: Cardiac MRI, 4D flow, Ferumoxytol, Congenital heart disease

Background

The management of congenital heart disease (CHD) relies on the ability to accurately assess cardiac structure, function, and hemodynamics. Cardiovascular magnetic
resonance imaging (CMR) provides accurate assessments of blood flow in CHD, with multiple methods to predict prognosis and aid decision making in diseases such as coarctation of the aorta, tetralogy of Fallot, anomalous pulmonary venous return, single ventricle defects, and others [1]. For single ventricle defects, CMR can accurately assess aortopulmonary collateral burden, pulmonary artery size, and ratio of pulmonary (Qp) to systemic (Qs) blood flow [2, 3]. It is an incredibly valuable noninvasive tool.

Specific applications within CMR, such as time-resolved phase-encoded CMR imaging with velocity encoding in three directions (4D Flow), have allowed for comprehensive, accurate assessment of hemodynamics by flow quantification over an entire volume in a single acquisition [4, 5]. Traditional two-dimensional phase contrast (2D-PC) CMR allows for measurements of flow in a single 2D plane. However, a separate acquisition for each vessel of interest must be performed, incurring a significant time cost. In contrast, 4D Flow CMR data is a single acquisition which allows for post-hoc measurements of velocity and flow in any vessel or plane of interest [6]. 4D Flow CMR is routinely performed in less than 10 min and with applications including visualization of blood flow patterns, flow direction, and velocity using color-coded streamlines [7].

The precision and acquisition duration of 4D Flow CMR can be optimized by administration of exogenous blood pool contrast agents, which shorten T1 relaxivity and improve contrast-to-noise ratios (CNR) [8]. Traditional agents include gadolinium-based contrast agents. More recently, ferumoxytol has emerged as an alternative for contrast-enhanced CMR imaging. Ferumoxytol is an ultra-small superparamagnetic iron oxide nanoparticle with an intravascular half-life of 14–15 h, compared to 5–36 min for gadolinium, allowing for marked signal enhancement of the entire intravascular blood pool [9, 10]. With the extended half-life of ferumoxytol, neonates can undergo unsedated free-breathing CMR studies where repeat acquisitions can be performed if there is motion artifact without re-dosing contrast, contributing to shorter scan times compared to gadolinium [11]. Ferumoxytol is an ideal contrast agent for use with 4D Flow CMR due to the acquisition length, as it allows for increased blood pool signal for a longer period of time compared to gadolinium [12].

As noninvasive CMR is being used to assess hemodynamics of smaller babies (i.e. double outlet right ventricle, interstage single ventricles at 4–6 kg) and in smaller vessels (i.e. pulmonary vein flow to measure total pulmonary blood flow in mixing lesions), it becomes important to understand what, if any, advantages contrast agents convey in the assessment of cardiothoracic blood flow using 4D Flow CMR [13, 14]. The purpose of this study was to assess the accuracy of 4D Flow CMR (as compared with 2D-PC) in ferumoxytol-enhanced CMR studies compared to gadolinium-enhanced CMR studies in small children with CHD.

**Methods**

**Study design and population**

This was a single-center retrospective, Institutional Review Board-approved study of 44 sequential CMR studies performed from October 2019 to October 2021. All CMR studies were clinically indicated and protocolled to answer salient clinical questions at the time of acquisition, per lab standard, on a 1.5 T CMR scanner (Aera, Siemens Healthineers, Erlangen, Germany). All included studies had both clinically relevant 2D-PC flows performed as well as a single 4D Flow CMR retrospectively gated acquisition. Acquisition parameters are found in Table 1 for both 2D-PC and 4D Flow acquisitions for 1.3 mm isotropic (up to 7 kg) and 1.8 mm isotropic (up to 25 kg) voxels, per lab standard. Contrast agent selection was at the discretion of the overseeing imager at the time of acquisition in accordance with institutional policy, which includes reviewing an information sheet in discussion with the patient and family members regarding safety and risks of contrast. In general, very ill infants, patients who required additional non-CMR studies during one sedation, and those with any history of drug allergies did not receive ferumoxytol during this study period. Clinically appropriate velocity encoding (VENC) for 2D-PC and 4D Flow CMR varied and were chosen by the overseeing imager at the time of acquisition, and based on velocities from the most recent echocardiogram while accounting for physiologic changes anticipated with sedation, if appropriate. The overseeing imager at the time of acquisition collected 2D-PC data for all clinically relevant vessels, thus the type of vessels where flow was measured varied patient-to-patient and by diagnosis. The 4D Flow measurements were then performed for each corresponding 2D-PC acquisition. Gadolinium-enhanced studies were performed with 0.1 mmol/kg of Dotarem (Guerbet, Villepinte, France) bolus for purposes of magnetic resonance angiography (MRA) acquisition, with 4D Flow acquisitions performed immediately following administration and 2D-PC completed within 18 ± 6 min on average. Ferumoxytol-enhanced studies were performed with 3 mg/kg of ferumoxytol (max 510 mg/dose) infused over 15 min just prior to entry to CMR suite. 2D-PC and 4D Flow CMR were completed within an average of 38 ± 8 min from the start of the scan. No studies were excluded for reasons of quality or artifacts.
Flow measurements
Measurements of both 4D Flow and 2D-PC datasets were obtained in the great vessels (aorta, main pulmonary artery, or proximal branch pulmonary arteries), systemic veins (right or left superior vena cava and inferior vena cava), and pulmonary veins (right and left upper and lower pulmonary veins), Fig. 1. Following selection of the cohort, the patients were randomized prior to analysis, without identification of type of contrast administered for each individual study. 4D Flow measurements were performed after background-phase correction on de-identified datasets by a single investigator trained in PC measurement (Arterys Inc., San Francisco, California, USA). All 2D-PC flow measurements were performed by the non-invasive imaging cardiologist at the time of image acquisition and were reported in the medical record. A subset of 40% of studies were made available for a second, blinded reader to perform 4D Flow CMR measurements for interobserver reliability analysis. Intraobserver reliability measurements were performed at the location of the ascending aorta vs. sinotubular junction, distal right pulmonary artery vs. proximal right pulmonary artery, and high superior vena cava vs. low superior vena cava.

Contrast-to-noise analysis
The CNR will vary with exogenous contrast administration, slice thickness and spatial resolution, which can affect accuracy of flow measurements regardless of contrast type selected. Therefore, the CNR was calculated, per 4D Flow acquisition, to assess the differences in signal intensity of the blood pool among the cohort in a similar manner to Mukai et al. [15]. Measurements were performed at end systole at the level of the aortic root in the transverse plane where corresponding 4D Flow measurements were obtained. The maximum aorta signal was obtained in the aortic root and the mean chest signal was obtained from sampling a portion of the distal lung fields away from central vasculature in the thoracic cavity. The standard deviation of noise in air was calculated from the mean of two samples outside the thoracic cavity, one anterior and midline to the chest wall and one anterior and rightward. CNR was calculated by dividing the difference between the maximum aorta signal and the mean chest signal by the standard deviation of noise in air, Fig. 2. Measurements were performed blinded to type of contrast agent administered and spatial resolution.

Low flow and single ventricle measurements
Subgroup analysis was performed comparing two ventricle CHD patients to a subset of 10 single ventricle patients comprised of five patients with ferumoxytol and five patients with gadolinium-enhanced images. Additionally, vessels with low flows (<1.5 L/min) were compared between the two ventricle and single ventricle cohorts. From the total cohort, the accuracy of ferumoxytol was compared to gadolinium when measuring arterial flows (aorta and pulmonary arteries) vs. venous flows (pulmonary veins and vena cavae).

Statistical analysis
All statistical analyses were performed with Prism 8 (Graphpad, San Diego, California, USA) with the
**Fig. 1** Cross-sectional view of a 5-year-old, 20 kg, single-ventricle patient status-post Glenn palliation demonstrating locations of 4D Flow quantification (black circles) positioned perpendicular to the axis of the vessel. Venous structures in diastole (left image) and arterial structures in systole (right image) were acquired in a single acquisition. Arterial and venous structures sampled include: right superior vena cava (RSVC), left superior vena cava (LSVC), left pulmonary artery (LPA), left upper pulmonary vein (LUPV), left lower pulmonary vein (LLPV), inferior vena cava (IVC), right lower pulmonary vein (RLPV), right upper pulmonary vein (RUPV), right pulmonary artery (RPA), and the aorta.

**Fig. 2** Contrast-to-noise (CNR) analysis performed by assessing multiple regions of interest (ROI), including the maximum signal in the aorta, mean signal in the chest (pleural cavity), and two separate samples to assess the standard deviation of noise in air outside the thoracic cavity.

\[
\text{CNR} = \frac{\text{Max Aorta} - \text{Mean Chest}}{\frac{\text{Std Dev Air 1} + \text{Std Dev Air 2}}{2}}
\]
exception of interobserver analysis, which was performed with MedCalc 12.2.1.0 (MedCalc Software, Ostend, Belgium). Demographic data (including age, body surface area (BSA), and vessel diameter) and CNR for the two contrast agents were compared using an unpaired t test. Ferumoxytol and gadolinium-enhanced 4D Flow CMR measurements were compared as percent difference from 2D-PC flow measurements using an unpaired t test. Simple linear regression was used to assess 4D Flow measurements in comparison to 2D-PC flow measurements from both ferumoxytol and gadolinium-enhanced images. For all tests, a P value < 0.05 was considered statistically significant. As part of the interobserver analysis, the intraclass correlation coefficient (ICC) reflected the average level of agreement between 4D flow measurements obtained by the primary investigator and a secondary reader. Similarly, for intraobserver analysis, the ICC reflected the average level of agreement between 4D flow measurements obtained in close proximity from the same vessel by the primary investigator.

### Results

#### Demographics

Measurements were obtained from 21 ferumoxytol-enhanced and 23 gadolinium-enhanced CMR studies. The patients included in this study were those with predominantly complex CHD including single ventricle anatomy, conotruncal anomalies, anomalous systemic or pulmonary venous drainage, and septal/atrioventricular valve anomalies. A subgroup analysis of 10 CMR studies focused on variability in measurements specifically in the single ventricle population.

The ferumoxytol and gadolinium administration groups were not statistically different with respect to average age (2.1 ± 1.6 vs. 2.3 ± 1.9 years), BSA (0.50 ± 0.2 m² vs. 0.52 ± 0.2 m²), proportion of single ventricle patients (24% vs. 22%), and average vessel diameter (great vessels (16.3 ± 5 vs. 15.7 ± 5.9 mm), branch pulmonary arteries (9.0 ± 3.1 vs. 9.5 ± 2.7 mm), pulmonary veins (7.2 ± 1.6 vs. 7.6 ± 2 mm), and systemic veins (13.7 ± 3.9 vs. 10.7 ± 3.8 mm), Table 2. There was only one patient with significant semilunar valve disease, classified as moderate

| Table 2 | Overall demographics | Ferumoxytol (n = 21) | Gadolinium (n = 23) | p value |
| --- | --- | --- | --- | --- |
| Age (years) | 2.1 ± 1.6 | 2.3 ± 1.9 | 0.841 |
| Male sex | 9 (43%) | 13 (57%) | 0.377 |
| Height (cm) | 81.8 ± 19.1 | 84.0 ± 18.3 | 0.706 |
| Weight (kg) | 11.5 ± 5.1 | 12.2 ± 4.8 | 0.599 |
| BSA (m²) | 0.5 ± 0.2 | 0.52 ± 0.2 | 0.667 |
| Great vessel diameter (mm) | 16.3 ± 5.0 | 15.7 ± 5.9 | 0.575 |
| Branch pulmonary arteries (mm) | 9.0 ± 3.1 | 9.5 ± 2.7 | 0.267 |
| Pulmonary vein diameter (mm) | 7.2 ± 1.6 | 7.6 ± 2.0 | 0.889 |
| Caval diameter (mm) | 12.7 ± 3.9 | 10.7 ± 3.8 | 0.115 |
| Diagnoses | | | |
| Single ventricle patients | 5 (24%) | 5 (22%) | 0.874 |
| Conotruncal anomalies | 7 (33%) | 13 (56%) | 0.129 |
| Anomalous systemic or pulmonary venous drainage | 6 (29%) | 3 (13%) | 0.211 |
| Septal defects and AV valve anomalies | 3 (14%) | 2 (9%) | 0.570 |
| Study indication | | | |
| Eval anatomy, function, chamber size, Qp:Qs | 10 (48%) | 10 (43%) | 0.789 |
| Eval outflow tract obstruction/regurgitation | 1 (4%) | 1 (4%) | 0.949 |
| Eval branch pa stenosis/flow differential | 5 (24%) | 8 (35%) | 0.437 |
| Pre-Glenn/Pre-Fontan | 5 (24%) | 4 (18%) | 0.608 |
| Use of anesthesia | | | |
| Moderate sedation or feed and bundle | 7 (33%) | 12 (52%) | 0.217 |
| General anesthesia—ventilated | 14 (67%) | 11 (48%) | 0.217 |
| Resolution 4D (mm) | | | |
| 1.30 x 1.25 x 1.25 | 15 (71%) | 3 (13%) | <0.001 |
| 1.80 x 1.75 x 1.75 | 6 (29%) | 20 (87%) | <0.001 |

Forty-four CMR studies from patients < 20 kg with congenital heart disease, 21 were performed with ferumoxytol and 23 with gadolinium. 10 were single ventricle patients, with 5 in the ferumoxytol cohort and 5 in the gadolinium cohort.
to severe truncal valve insufficiency in the gadolinium cohort. There was no statistical difference in the proportion of patients in either cohort that received moderate sedation vs. general anesthesia ($p = 0.217$). All 4D Flow CMR acquisitions were performed free-breathing with respiratory navigation, regardless of type of anesthesia administered. No contrast reactions were noted following administration of either ferumoxytol or gadolinium. Lastly, given the higher expected CNR, more patients given ferumoxytol were imaged with a higher resolution compared to gadolinium-based contrast.

**4D flow vs. 2D-PC flow analysis**

Ferumoxytol-enhanced 4D Flow CMR measurements demonstrated less percent difference from 2D-PC flow measurements when compared to gadolinium-enhanced studies (mean difference = 7.9 vs. 13, $p = 0.01$). This finding was even more pronounced in the single ventricle cohort with improved accuracy of flow measurements obtained from ferumoxytol-enhanced images compared to gadolinium (mean difference = 6.1 vs. 17.6, $p = 0.001$), Fig. 3A. In the subgroup analysis of vessels in single ventricle patients with low flows, defined as less than 1.5 L/min, ferumoxytol-enhanced 4D Flow CMR measurements had stronger correlation to 2D-PC flow than gadolinium-enhanced measurements, Fig. 3B.

In the subgroup analysis of arterial (aorta and pulmonary artery) vs. venous (pulmonary veins and vena cava), ferumoxytol-enhanced 4D Flow CMR measurements demonstrated less percent difference from 2D-PC flow measurements when compared to gadolinium-enhanced studies, Fig. 4A. This finding was more pronounced in the venous flow measurements (mean difference = 6.1 vs. 16.6, $p = 0.001$). Additional analysis was performed to assess the difference between the various types of vessels analyzed, Fig. 4B. Ferumoxytol-enhanced 4D Flow CMR measurements demonstrated less percent difference from 2D-PC flow measurements, which was statistically significant in the branch pulmonary arteries, systemic veins, and pulmonary veins ($p = 0.008$, $p = 0.028$, and $p = 0.030$ respectively).
Pulmonary venous flow measurements were isolated and analysis of 4D Flow CMR measurements acquired with low (150–200 cm/s) vs. high (250–375 cm/s) VENC was performed, Fig. 5. Ferumoxytol-enhanced 4D flow measurements demonstrated less percent difference from 2D-PC flow measurements in the low VENC cohort (mean difference = 6.8 vs. 20.3, p = 0.003), but there was no statistical difference in the high VENC cohort. In summary, all ferumoxytol-enhanced 4D flow measurements across all vessels had <10% difference from 2D-PC measurements, compared to gadolinium which had >10% difference.

**Contrast to noise analysis**

There was a significant difference between the CNR in ferumoxytol studies with a spatial resolution of 1.3 mm (92 ± 34, n = 14) vs. 1.8 mm (185 ± 81, n = 6; p = 0.002). There was no significant difference in the CNR between gadolinium-enhanced studies performed at a spatial resolution of 1.3 mm vs. 1.8 mm. The CNR in ferumoxytol studies with a spatial resolution of 1.3 mm (92 ± 34, n = 14) was still higher than the CNR in gadolinium studies with a spatial resolution of 1.8 mm (69 ± 21, n = 20; p = 0.036), Fig. 6.

**Interobserver analysis**

The ICC values reflecting the average level of agreement between 4D Flow CMR measurements obtained by the primary investigator and a secondary observer were over 95%, demonstrating excellent agreement between observers. Specifically, the ICC for ferumoxytol-enhanced 4D Flow CMR measurements was 0.997 (0.994–0.999) and similarly 0.985 (0.970–0.992) for gadolinium-enhanced 4D Flow CMR. Bland–Altman analysis in Fig. 7A
demonstrates excellent agreement between observers for both contrast agents. The ICC values reflecting the average level of agreement between 4D Flow CMR measurements obtained by the primary investigator were over 95%, demonstrating excellent agreement. Specifically, the ICC for ferumoxytol-enhanced 4D Flow CMR measurements was 0.999 (0.998–0.999) and similarly 0.998 (0.995–0.999) for gadolinium-enhanced measurements. Bland–Altman analysis in Fig. 7B demonstrates excellent agreement between repeat measurements sampled in selected vessels by the primary investigator.

**Discussion**

This study demonstrates excellent accuracy of 4D Flow CMR measurements (compared to 2D-PC flow measurements) in children less than 20 kg with CHD. Additionally, ferumoxytol-enhanced studies provide outstanding 4D Flow accuracy, and this is demonstrated most significantly in small children with single ventricles, small vessels, and low-velocity vessels (i.e. venous structures). These data support the use of ferumoxytol-enhanced studies in children, and particularly in children with complex CHD where it is necessary to measure flow in many thoracic vessels of varying size and peak velocities. Further, ferumoxytol-enhanced 4D Flow CMR studies had higher CNR than gadolinium-enhanced studies, even with a smaller spatial resolution.

The accuracy of measuring both intracardiac and extracardiac flows is paramount in the surgical planning of patients with complex CHD. This is especially true in neonates where measurements are performed in small-caliber vessels with low flow rates, thus requiring high spatial resolution and optimization of CNR to maintain accuracy. For example, in single ventricle patients, quantification of AP collateral burden requires flow measurements in vessels of varying size, including the branch pulmonary arteries, pulmonary veins, inferior and superior vena cava, and aortic outflow. The mean difference of ferumoxytol-enhanced 4D Flow CMR measurements in the single ventricle cohort was 6.1, in comparison to 17.6 for 2D-PC flow measurements (p = 0.001). When measuring small vessels in patients < 20 kg, these differences in flow measurements may become compounded and could become clinically significant when performing measurements of Qp:Qs, differential pulmonary blood flow, etc. Current research has even proposed utilizing hemodynamic data collected solely from CMR, instead of performing the traditional pre-Fontan cardiac catheterization [16]. 4D Flow CMR has proven to be accurate in assessment of blood flow and shunt quantification performed at multiple levels of the vascular tree, including
Flow magnitudes in the CHD population are often less than 2 L/min and may require repeat acquisitions with adjustment of VENC due to aliasing of blood flow [18]. VENC adjustments are possible with 2D-PC CMR, however, standard 4D Flow CMR acquisitions require a single VENC, typically set to 1.5 m/s [19]. The average flow of all 170 vessels (arterial and venous) measured in our study was $1.3 \pm 0.9$ L/min and mean vessel size was $11.8 \pm 5.3$ mm. With vessels of this caliber, higher spatial resolution is desired, however, there are limitations of spatial resolution with gadolinium-enhanced 4D Flow CMR studies. With improved spatial resolution, there is a concordant decrease in CNR and signal-to-noise ratio (SNR), thus the clinician must balance the benefit between these two factors. This study demonstrated improved CNR with use of ferumoxytol at a spatial resolution of 1.8 mm, but also noted the CNR was still higher than what could be achieved by gadolinium at a resolution of 1.3 mm.

Ferumoxytol has many advantages over gadolinium, including its extended intravascular half-life of approximately 15 h, compared to gadolinium which is closer to 29 min [11]. The extended half-life allows for repeat scans if needed without re-dosing of the contrast agent. Gadolinium has some advantages over ferumoxytol in that there is risk of anaphylaxis associated with ferumoxytol, although this was not observed in our cohort [20]. Post-market surveillance of approximately 1.2 million doses of ferumoxytol administered from 2009 to 2015 by the United States Food & Drug Administration Adverse Event Reporting System noted 79 anaphylactic reactions with 18 fatalities, resulting in the boxed warning issued in March 2015. Of these fatalities, 24% of the patients had multiple drug allergies [21]. Additionally, there have been reports of hypotension with use of ferumoxytol, however, recent studies in pediatric patients undergoing CMR have shown the incidence of hypotension did not differ between ferumoxytol and gadolinium [22]. Gadolinium, however, carries the risk of renal toxicity, and in rare cases, nephrogenic systemic fibrosis [23]. Lastly, late gadolinium enhancement allows for assessment of myocardial tissue characteristics, which can be useful in determining both diagnosis and prognosis [24].

2D-PC CMR has proven potential as the new gold-standard for flow volume quantification in place of the formerly accepted, highly variable technique of thermodilution through invasive cardiac catheterization [25]. Presently, there has been a focus on the validation of newer and more accurate quantification of blood flow through 4D Flow CMR [26, 27]. Previous studies have demonstrated that 4D Flow CMR can be performed with sufficient resolution to accurately measure ventricular volume, mass, and function that is reproducible in comparison to that of cine balanced steady-state free precession [28]. 4D Flow data can be collected in a single acquisition, whereas 2D-PC data is collected as separate acquisitions to measure the flow in each vessel of interest, leading to increased scan times and prolonged exposure to neurotoxic effects of anesthesia [29]. Prior studies have demonstrated average 4D Flow CMR scan times of 12 min, with a range from 4 to 20 min, leading to reduction in the total CMR scan time [19]. Importantly, since a single 4D Flow data set acquires both systemic and pulmonary inflow and outflow at the same time, the 4D Flow calculations are internally validated [25]. This can be beneficial in CHD patients with hemodynamic instability where time between measurements can lead to variations in blood flow or degree of shunting, causing inaccuracies in the data obtained. With the use of ferumoxytol and 4D Flow, there is potential for less utilization of 2D-PC, leading to shorter duration of CMR scans, as well as avoidance of anesthesia for breath holds.

Previous work has focused predominantly on the reproducibility of 4D Flow CMR measurements to 2D-PC CMR using a single contrast agent for comparison. There has been some investigation of 4D Flow CMR image quality using gadolinium vs. ferumoxytol, focusing on comparison of volumetric measurements [15]. Our study is the first to validate ferumoxytol as an ideal contrast agent in small infants with CHD. It allows for highly reproducible quantification of blood flow between 4D Flow and 2D-PC CMR, compared to the more traditional use of gadolinium. This study is also unique in that it focuses on the measurements obtained from CHD patients with small caliber vessels and low flow rates. Our findings support the use of ferumoxytol as a superior contrast agent to gadolinium and provide justification for use of 4D Flow for quantification of blood flow over traditional 2D-PC flow measurements. The ability to obtain accurate, reproducible measurements will help identify optimal measures of hemodynamics that correlate with favorable measures of cardiac function and favorable clinical outcomes.

Limitations
The study is limited in that it was performed in a single center in a retrospective manner. Because the choice to administer gadolinium vs. ferumoxytol was clinical in nature, and not systematically varied, this may have introduced bias into the cohorts receiving each contrast agent. However, there were no significant differences in any clinical variable between the two cohorts, so likely any bias was minimized. The sample size was small, although large enough to demonstrate significant
reproducibility of 4D Flow CMR measurements in comparison to 2D-PC flow. Implications of the small sample size may lead to type II error and failure to reject the null hypothesis. The inequal distribution of gadolinium-enhanced studies performed at a spatial resolution of 1.3 mm (n = 3) vs. 1.8 mm (n = 20) may have contributed to the insignificant difference in the CNR between these two groups. Additionally, the 4D Flow CMR measurements were performed on a single platform with customized eddy-current phase correction to minimize vendor variability. Further investigation to determine variability between different vendor platforms and different background correction methods are needed. Additionally, the 2D-PC flow measurements were performed in a clinical setting by various trained non-invasive imaging cardiologists where the spatial resolution, velocity encoding, and scanning time were determined independently based on patient-specific clinical indications. In contrast, the 4D Flow CMR measurements were performed by an independent operator in a research setting. There were undoubtedly more patients in the gadolinium cohort with a spatial resolution of 1.8 mm, which is a limitation of the retrospective nature of this study. However, our results demonstrate the improved ability to augment CNR with ferumoxytol, even at a spatial resolution of 1.3 mm in comparison to gadolinium enhanced studies at 1.8 mm.

**Conclusion**

Ferumoxytol-enhanced 4D Flow CMR is a highly reliable technique and has improved accuracy when compared to gadolinium, particularly for low flow vessels in small single ventricle CHD patients. Given the improved accuracy of ferumoxytol, its extended intravascular half-life, and marked signal enhancement, it is an ideal contrast agent for use in infants with complex CHD.

**Abbreviations**

4D flow: Time-resolved three-dimensional phase-contrast; 2D-PC: Two-dimensional phase contrast; BSA: Body surface area; CHD: Congenital heart disease; CMR: Cardiovascular magnetic resonance; CNR: Contrast-to-noise ratio; IVC: Inferior vena cava; LLPV: Left lower pulmonary vein; LPA: Left pulmonary artery; LSVC: Left superior vena cava; LUPV: Left upper pulmonary vein; Qp: Pulmonary blood flow; Qs: Systemic blood flow; RLPV: Right lower pulmonary vein; ROI: Region of interest; RPA: Right pulmonary artery; RSVC: Right superior vena cava; RUPV: Right upper pulmonary vein; VENC: Velocity encoding.

**Acknowledgements**

The authors would like to acknowledge the expertise and support provided by CMR technicians Nicholas Mouzakis and Haiyan Wang in scanning these small children.

**Author contributions**

SK was responsible for the study design, analysis of CMR measurements, interpretation of results and writing the manuscript. MU contributed to analysis of CMR measurements and writing the manuscript. YHL, JM, and RC contributed to the interpretation of results and writing the manuscript. LO contributed to the study design, interpretation of results and writing the manuscript. All authors read and approved the final manuscript.

**Funding**

The authors have no external funding to report.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This retrospective study was approved by the Institutional Review Board. Waiver of consent was obtained. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare they have no competing interests.

**Author details**

1 Division of Pediatric Cardiology, Children’s National Hospital, 111 Michigan Ave NW, WW 300, Washington, DC 20010, USA. 2 Division of Pediatric Cardiology, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA.

**Received:** 24 February 2022  **Accepted:** 30 August 2022  **Published online:** 10 November 2022

**References**

1. Fratz S, Chung T, Greil GF, et al. Guidelines and protocols for cardiovascular magnetic resonance in children and adults with congenital heart disease: SCMR expert consensus group on congenital heart disease. J Cardiovasc Magn Reson. 2013;15(1):51. https://doi.org/10.1186/1532-429X-15-51.

2. Hart MR, Whiteside W, Yu S, et al. Differences in pulmonary and systemic flow measurements by cardiac magnetic resonance vs cardiac catheterization and relation to collateral flow in single ventricle patients. Pediatr Cardiol. 2020;41(5):885–91. https://doi.org/10.1007/s00246-020-02327-w.

3. Vasanawala SS, Hannekman K, Alley MT, Hsiao A. Congenital heart disease assessment with 4D flow MRI. J Magn Reson Imaging. 2015;42(4):870–86. https://doi.org/10.1002/jmri.24856.

4. Markl M, Chan FP, Alley MT, et al. Time-resolved three-dimensional phase-contrast MRI. J Magn Reson Imaging. 2005;17(4):499–506. https://doi.org/10.1002/jmri.10272.

5. Hope MD, Meadows AK, Hope TA, et al. Clinical evaluation of aortic coarctation with 4D flow MR imaging. J Magn Reson Imaging. 2010;31(3):711–8. https://doi.org/10.1002/jmri.22083.

6. Hsiao A, Alley MT, Massaband P, Herfkens RJ, Chan FP, Vasanawala SS. Improved cardiovascular flow quantification with time-resolved volumetric phase-contrast MRI. Pediatr Radiol. 2011;41(6):711–20. https://doi.org/10.1007/s00247-010-1932-z.

7. Warmerdam E, Kingtons GJ, Leiner T, Grotenhuis HB. Three-dimensional and four-dimensional flow assessment in congenital heart disease. Heart. 2020;106(6):421–6. https://doi.org/10.1136/heartjnl-2019-315797.

8. Krishnamurthy R, Bahouth SM, Muthupillai R. 4D contrast-enhanced MR angiography with the keyhole technique in children: technique and clinical applications. Radiographics. 2016;36(2):523–37. https://doi.org/10.1148/rg.2016150106.

9. McCullough BJ, Kolokythas O, Maki JH, Green DE. Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging. 2013;37(6):1476–9. https://doi.org/10.1002/jmri.23879.
10. Camren GP, Wilson GJ, Bamra VR, Nguyen QK, Hippe DS, Maki JH. A comparison between gadofosveset trisodium and gadobenate dimeglumine for steady state MRA of the thoracic vasculature. Med Biol Eng Comput. 2014;2014:625614. https://doi.org/10.1155/2014/625614.

11. Lai LM, Cheng JY, Alley MT, Zhang T, Lustig M, Vasanawala SS. Feasibility of ferumoxytol-enhanced neonatal and young infant cardiac MRI without general anesthesia. J Magn Reson Imaging. 2017;45(5):1407–18. https://doi.org/10.1002/jmri.25482.

12. Cheng JY, Hanneman K, Zhang T, et al. Comprehensive motion-compensated highly-accelerated 4D flow MRI with ferumoxytol enhancement for pediatric congenital heart disease. J Magn Reson Imaging. 2016;43(6):1535–68. https://doi.org/10.1002/jmri.25106.

13. Kellenberger CJ, Yoo SJ, Buchel ERV. Cardiovascular MR imaging in neonates and infants with congenital heart disease. Radiographics. 2007;27(1):5–18. https://doi.org/10.1148/rg.271065027.

14. Geiger J, Callaghan FM, Burkhardt BEU, Valsangiacomo Buechel ER, Kellenberger CJ. Additional value and new insights by four-dimensional flow magnetic resonance imaging in congenital heart disease: application in neonates and young children. Pediatr Radiol. 2021;51(8):1503–17. https://doi.org/10.1007/s00247-020-04885-w.

15. Mukai K, Burris NS, Mahadevan V5, Foster ED, Ordovas KG, Hope MD. 4D flow image quality with blood pool contrast: a comparison of gadofosveset-trisodium and ferumoxytol. Int J Cardiovasc Imaging. 2018;34(2):273–9. https://doi.org/10.1007/s10554-017-1224-x.

16. Fogel MA, Pawlowski TW, Whitehead KK, et al. Cardiac magnetic resonance imaging in neonates and infants: the impact on long-term neurodevelopment. J Clin Pharmacol. 2018;58(Suppl 10):S140–50. https://doi.org/10.1186/s12968-017-01226-z.

17. Chelu RG, Horowitz MJ, El-Said HG, Alshawabkeh L, Kligerman SJ, Hsiao KM, Ramamoorthy C. Safety of ferumoxytol in children undergoing cardiac catheterization. Radiol Cardiothorac Imaging. 2021;3(2):e200446. https://doi.org/10.1002/rci.1139.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions